634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I

A phase 2 open label study of the safety tolerability pharmacokinetics pharmacodynamics and efficacy of DISC 3405 in participants with polycythemia vera PV

Improvemf Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate 2 or high risk myelofibrosis

A multicenter open label phase 1 study of INCB160058 a first in class JAK2V617F mutant–selective inhibitor in patients with myelofibrosis polycythemia vera or essential thrombocythemia

Real world evidence demonstrates superior overall survival and favorable safety of avapritinib over midostaurin in newly diagnosed advanced systemic mastocytosis

Disparities related to myelofibrosis A retrospective analysis of US mortality data

Epidemiology and outcomes of patients with myeloproliferative neoplasms in the United States A SEER database analysis years 2000 2021

Impact of early dose escalation and treatment duration on hematologic response in ropeginterferon alfa 2b treatment for polycythemia vera

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Interferon alfa treatment of early primary myelofibrosis is associated with improved overall survival

RALLY MF A phase 2 Study of DISC 0974 an anti hemojuvelin antibody in patients with myelofibrosis and anemia

Treatment landscape and outcome of myeloproliferative neoplasms in asia Interim analysis of the Asian myeloproliferative neoplasm registry

Transcriptomic signatures associated with deep molecular response to ropeginterferon alfa 2b in polycythemia vera

Long term efficacy and safety of ropeginterferon alfa 2b under its hidat regimen for the treatment of polycythemia vera

Circulating cell free BRAFV600E as a biomarker in patients with erdheim chester disease

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms MPN and autoimmune disorders

Distinctive features of patients with MPN during pregnancy Thrombotic risk molecular drivers and differential outcomes by subtype

Detection of mutation in cell free DNA predicts poor outcomes in adult patients with langerhans cell histiocytosis

Shorespan 017 Phase 3 extension study for safety of bomedemstat in participants with essential thrombocythemia who received bomedemstat from a prior clinical study

Final results from a prospective multicenter non interventional study BESREMi PASS on the safety of ropeginterferon alfa 2b in 229 patients with polycythemia vera

Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib A systematic review and meta analysis

Effect of avapritinib on skin lesions in patients with advanced systemic mastocytosis using a novel artificial intelligence based technology

Ferritin change and predictors of anemia response in ruxolitinib intolerant myelofibrosis patients treated with gecacitinib

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

A phase 1 2a trial of amsulostat a novel pan lysyl oxidase inhibitor in patients with advanced myelofibrosis as an add on to ruxolitinib treatment for up to 52 weeks

Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the Phase 3 SIMPLIFY 1 trial

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib Post hoc analyses of SIMPLIFY 1 and MOMENTUM

Identification of red cell distribution width as a key predictor of leukemic transformation in polycythemia vera and essential thrombocythemia A machine learning approach involving 10 560 cases

Pacritinib in patients with high risk myelofibrosis Outcomes from post hoc analyses of two Phase 3 studies

Nuvisertib an oral investigational selective PIM1 kinase inhibitor showed clinical responses strongly correlating with cytokine modulation in patients with relapsed refractory myelofibrosis in the ongoing global phase I II study

Diagnostic relevance of SH2B3 mutations in suspected myeloid malignancies Insights from a large scale NGS based screening study

Real world risk of vascular events in patients with myeloproliferative neoplasms compared to the danish general population